# Study of YKYY032 Injection in Adults With Hyperlipoproteinemia (a)

Study · id `cardio:ct-nct07914660` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07914660](<https://clinicaltrials.gov/study/NCT07914660>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07914660

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 192 participants.

## Technical summary

Registry record NCT07914660. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-20 (anticipated); primary completion 2028-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 192 participants (planned count; ClinicalTrials.gov record NCT07914660, source copy `cardio:ctgov-nct07914660-2026-11-03`, retrieved 2026-11-18)
- Planned start: 2026-11-20 (anticipated) (ClinicalTrials.gov record NCT07914660, source copy `cardio:ctgov-nct07914660-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2028-12-30 (anticipated) (ClinicalTrials.gov record NCT07914660, source copy `cardio:ctgov-nct07914660-2026-11-03`, retrieved 2026-11-18)
- Completion: 2029-05-31 (anticipated) (ClinicalTrials.gov record NCT07914660, source copy `cardio:ctgov-nct07914660-2026-11-03`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07914660, source copy `cardio:ctgov-nct07914660-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07914660-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: Study of YKYY032 Injection in Adults With Hyperlipoproteinemia (a)
- Condition: Hyperlipoproteinemia (a)
- Intervention (Drug): YKYY032 group
- Intervention (Other): YKYY032 Placebo group
- Lead sponsor: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: d414ade576b2f3e8d74a8db21b1698adf6f0c52fe76084e5ddd0ec1c62abfb89
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
